Current and Emerging Pharmacological Therapies for Hypertriglyceridemia
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27083573 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ibrahim S Alhomoud. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah 51452, Qassim, Saudi Arabia. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Hypolipidemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qassim University, Deanship of Graduate Studies and Scientific Research at Qassim University.
Abstract (Originalsprache)
Hypertriglyceridemia is a well-recognized contributor to residual atherosclerotic cardiovascular disease risk and a predisposing factor for acute pancreatitis. Despite the availability of pharmacologic agents and lifestyle interventions, patients with severe and refractory hypertriglyceridemia often fail to achieve adequate control. Recent advances in the molecular understanding of triglyceride metabolism have driven the development of targeted therapies that selectively modulate key regulatory pathways. This study sought to provide an overview of triglyceride regulation, the atherogenic role of remnant lipoproteins, and clinical evidence of emerging triglyceride-lowering therapies. Lipoprotein metabolism is regulated by a complex network of regulatory proteins that include lipoprotein lipase (LPL), apolipoproteins such as apolipoprotein C-III (ApoC-III), and angiopoietin-like proteins (ANGPTLs). Targeting these proteins in the metabolic cascade has shown promising results in reducing triglyceride levels. Emerging therapies such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) directed against ApoC-III (volanesorsen, olezarsen, and plozasiran), inhibitors of ANGPTL3 (evinacumab and zodasiran), and fibroblast growth factor 21 (FGF-21) analogs (pegozafermin) have demonstrated substantial triglyceride-lowering efficacy. These agents have achieved reductions in triglyceride levels of up to 80% in clinical trials. Additionally, preliminary evidence suggests that these agents may also reduce the incidence of acute pancreatitis and improve cardiometabolic risk profiles, although dedicated trials are still needed to confirm these outcomes. The therapeutic landscape for hypertriglyceridemia is rapidly evolving. Integrating these novel agents into clinical practice will require individualized treatment plans, sustained lifestyle modification, and careful safety monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah 51452, Qassim, Saudi Arabia.
ORCID-Profile: Ibrahim S Alhomoud
Förderung
- Qassim University
- Deanship of Graduate Studies and Scientific Research at Qassim University
Zitieren
APA
Alhomoud, I. S. (2026). Current and Emerging Pharmacological Therapies for Hypertriglyceridemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083573
Vancouver
Alhomoud IS. Current and Emerging Pharmacological Therapies for Hypertriglyceridemia. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27083573
BibTeX
@article{Alhomoud2026,
author = {Alhomoud, Ibrahim S},
title = {Current and Emerging Pharmacological Therapies for Hypertriglyceridemia},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27083573}
}
EUVIMED